Lbp Am Sa Grows Stock Position in DexCom, Inc. (NASDAQ:DXCM)

LBP AM SA grew its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 5.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 215,810 shares of the medical device company's stock after buying an additional 10,320 shares during the quarter. LBP AM SA owned 0.06% of DexCom worth $16,784,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Skandinaviska Enskilda Banken AB publ grew its holdings in DexCom by 3.5% in the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 283,654 shares of the medical device company's stock worth $22,114,000 after acquiring an additional 9,668 shares during the last quarter. Vestcor Inc boosted its holdings in shares of DexCom by 26.2% during the fourth quarter. Vestcor Inc now owns 15,832 shares of the medical device company's stock worth $1,231,000 after purchasing an additional 3,291 shares during the period. Avantax Advisory Services Inc. grew its stake in shares of DexCom by 34.4% in the fourth quarter. Avantax Advisory Services Inc. now owns 7,184 shares of the medical device company's stock worth $559,000 after purchasing an additional 1,840 shares during the last quarter. Great Lakes Advisors LLC purchased a new position in DexCom during the 4th quarter valued at about $3,426,000. Finally, Sequoia Financial Advisors LLC raised its position in DexCom by 35.5% during the 4th quarter. Sequoia Financial Advisors LLC now owns 8,489 shares of the medical device company's stock valued at $660,000 after purchasing an additional 2,222 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

DexCom Stock Down 0.9 %

DXCM stock traded down $0.65 on Tuesday, reaching $70.70. 2,603,978 shares of the company traded hands, compared to its average volume of 3,881,061. The firm has a fifty day simple moving average of $83.82 and a 200-day simple moving average of $76.94. The company has a market cap of $27.63 billion, a P/E ratio of 49.44, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Buying and Selling at DexCom

In other news, EVP Jereme M. Sylvain sold 2,090 shares of the firm's stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the sale, the executive vice president now owns 83,526 shares of the company's stock, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Kevin R. Sayer sold 33,359 shares of DexCom stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the sale, the chief executive officer now owns 319,037 shares of the company's stock, valued at $27,727,505.67. This represents a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 104,657 shares of company stock worth $8,019,422. 0.30% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on DXCM. Morgan Stanley lifted their price objective on DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a research report on Friday, February 14th. Citigroup lifted their price target on shares of DexCom from $101.00 to $104.00 and gave the company a "buy" rating in a report on Tuesday, March 4th. Redburn Atlantic raised shares of DexCom from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Wells Fargo & Company reaffirmed an "overweight" rating on shares of DexCom in a research report on Saturday, March 8th. Finally, Baird R W upgraded shares of DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 16th. Four analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $99.82.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.